A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Inclusion criteria: * Age ≥ 18 years old and ≤ 65 years old. * Patients with metastatic CRC. Confirmation of CRC diagnosis by histological or cytological specimen from original resection of primary tumor. * Patients who progressed despite prior therapy with FOLFOX (5FU and oxaliplatin) plus bevacizumab or XELOX (capecitabine and oxaliplatin) plus bevacizumab. * Patients with at least one measurable lesion by RECIST as determined by Computer Tomography (CT) Scan, Magnetic Resonance Imaging (MRI) or physical examination. * Patients with a WHO performance status of 0 or 1. Exclusion criteria: * Patients with Gilbert's syndrome or any other syndrome associated with deficient glucoronidation of bilirubin. * Patients who are homozygous for the UGT1A1\*28 allele as determined by sequencing. * Patients who have received previous irinotecan-based therapy. * Prior treatment with an mTOR inhibitor. Other protocol-defined inclusion/exclusion criteria may apply